Navigation Links
Pufferfish neurotoxin may serve as treatment for cancer therapy related pain
Date:6/26/2013

HACKENSACK, N.J. (June 26, 2013)- Researchers at the Brain and Spine Institute at John Theurer Cancer Center at HackensackUMC, one of the nation's 50 best hospitals for cancer, are studying a possible alternative to side effect-ridden opioid-based medications to treat cancer-related pain. The active ingredient for the treatment is Tetrodotoxin, a neurotoxin found in pufferfish.

"Chemotherapy-induced neuropathic pain is a serious debilitating condition that occurs in over 40 percent of patients receiving chemotherapy," said Principal Investigator Samuel Goldlust, M.D., Co-Chief of the Brain and Spine Institute at John Theurer Cancer Center. "Tetrodotoxin has been found to be 3,000 times more potent than morphine without the negative side effects of opioids."

Caused by damage to neurons in the peripheral nervous system, chemotherapy-induced neuropathic pain is one of the most common reasons that cancer patients stop their treatment early, negatively affecting patient outcomes. For some patients, the symptoms persist after chemotherapy for months, years, or even indefinitely.

Until recently, chemotherapy-induced neuropathic pain, was treated primarily with opioids, anti-depressants or drugs primarily used to treat seizures. Scientists have learned more recently of the importance of sodium channels in the conduction of pain signals from peripheral nerves to the brain. Derived from a neurotoxin found in pufferfish, Tetrodotoxin targets sodium channels in the patient's peripheral nervous system. By blocking the sodium channels, Tetrodotoxin limits the conduction of pain signals to the central nervous system, offering relief from pain related to damage caused by chemotherapy.

Many species of marine pufferfish contain a large amount of Tetrodotoxin in their skin and tissues as an evolutionary adaptation to reduce predation. The dose used in this clinical trial needed for pain relief is approximately 300 times less than the total found in one fish.

"WEX is committed to developing a new class of non-opioid analgesics," said Mr. Walter Korz, VP, & General Manager of WEX Pharmaceuticals. "We are honored to have an institution such as John Theurer Cancer Center at HackensackUMC participating with Dr. Goldlust serving as Principal Investigator for this groundbreaking multicenter phase II clinical trial using Terodotoxin."

"Novel approaches to treatment are accelerating cancer care at an unprecedented rate," said Andre Goy M.D., M.S., Chairman and Director, and Chief of Lymphoma, John Theurer Cancer Center and Chief Science Officer and Director of Research and Innovation of Regional Cancer Care Associates. "We believe it is important that our researchers are actively involved in shaping the future of cancer care through clinical trials such as this one."

"Clinical trials allow us to continue offering the most advanced treatments options to our patients to improve outcomes and quality of life," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer, Professor, and Vice President of Cancer Services and President of Regional Cancer Care Associates, LLC.


'/>"/>

Contact: Jon Byington
jon.byington@porternovelli.com
212-601-8208
John Theurer Cancer Center
Source:Eurekalert

Related medicine news :

1. MS researchers determine that brain reserve independently protects against cognitive decline in MS
2. University of New England and Partners Celebrate Opening of Portland Community Health Center at Riverton June 20 for Underserved Populations
3. Effective Environmental Services Launch New Websites to Serve Customers
4. Allsup Observes National HIV Testing Day June 27
5. Merrill DataSite Releases New Comments: Cash Reserves and M&A Options
6. New Water Select® Showerhead Valve Conserves Water & Saves Money
7. On The Road to Better Health – Newark Residents to Be Served by New Mobile Health Center
8. PD-like sleep and motor problems observed in α-synuclein mutant mice
9. Fuseideas Expands to Serve Midwest Clients
10. Allsup Observes National Disability Professionals Week – June 10-14
11. Newport Board Group, a National Business Advisory Firm of CEOs That Serves the Middle Market, Issues Guidance for Companies Considering a Sale in 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Angeles, CA (PRWEB) , ... February 23, 2017 , ... ... first two episodes of WE TV’s “Mama June: From Not to Hot,” which will ... TV notable, “Mama” June Shannon, known to millions from the 2012 reality television series, ...
(Date:2/23/2017)... IPSWICH, Mass. (PRWEB) , ... February 23, 2017 ... ... chosen as an approved content provider for the National Institute for Health ... care and social care-related organizations in the National Health Service (NHS) to search, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink ... publication where generations converge and explore the world from different perspectives. By providing ... enables readers to gain understanding, increase empathy, and find greater happiness. , ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... the pre-eminent publication and community for those in the fight against cancer, has ... important in their success. HRA will release top-line findings in a webinar, ...
(Date:2/23/2017)... ... ... CALNOC, the nation’s first and only nursing quality indicators database today announced ... and Collaboration – in Seattle, WA on October 23, 2017. , Dr. Gary Kaplan ... Seattle since 2000. In addition to his role at Virginia Mason, Dr. Kaplan also ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Feb 23, 2017 Research and Markets has ... Analysis and Strategies - 2016" report to their offering. ... The latest research ... drug pricing data and benchmarks in the global Autism Spectrum Disorder ... What are the key drugs marketed for Autism Spectrum ...
(Date:2/23/2017)... -- ITL Limited, ( ASX: ITD ), an innovative diversified healthcare ... ended 31 December 2016 compared with the previous corresponding period. A ... here . Highlights ... Earnings per share of 2.2 cents (Dec 2015: 1.2 ... $15.7m; up 11%) Profit before tax of $2.12m ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Analysis and Strategies - 2016" report to their offering. ... The latest research ... pricing data and benchmarks in the global Oesophageal Cancer market. ... What are the key drugs marketed for Oesophageal Cancer and ...
Breaking Medicine Technology: